Objectives:Accumulating evidence suggests that people living in cold regions have a higher risk of developing coronary atherosclerotic heart disease(CHD).Long non-coding RNAs(lncRNAs)have been implicated in the pathog...Objectives:Accumulating evidence suggests that people living in cold regions have a higher risk of developing coronary atherosclerotic heart disease(CHD).Long non-coding RNAs(lncRNAs)have been implicated in the pathogenesis and treatment of a variety of diseases.The present study aimed to investigate the serum level of lncRNA-taurine upregulated gene 1(TUG1)in patients with CHD and assess its potential as a diagnostic biomarker.This study aimes to investigate the serum level of lncRNA-TUG1 in patients with CHD and assess its potential as a diagnostic biomarker.Methods:The Gene Expression Omnibus(GEO)database was employed to identify the potential lncRNAs serving as biomarkers for CHD.To validate lncRNA-TUG1,232 subjects were enrolled in both test and diagnostic cohorts.Serum lncRNA-TUG1 levels were measured by RT-qPCR.The association between lncRNA-TUG1 levels and CHD severity was analyzed using Pearson's correlation test.Diagnostic value was assessed by receiver operating characteristic(ROC)curve analysis and compared with established cardiac biomarkers.Results:LncRNA-TUG1 was identified in the GEO database as a potential biomarker for CHD.Serum lncRNA-TUG1 levels were significantly higher in CHD patients compared with healthy controls and non-CHD patients.CRP levels also differed between CHD and non-CHD groups,while other biomarkers showed no significant differences.ROC curve analysis demonstrated that lncRNA-TUG1 could distinguish CHD from non-CHD patients,with an area under the curve(AUC)of 0.8916,which was higher than that of conventional biomarkers such as cTnI.At a cut-off value of 2.311,the sensitivity and specificity of lncRNA-TUG1 were 61.63%and 97.67%,respectively,surpassing the diagnostic performance of cTnI.Furthermore,lncRNA-TUG1 levels in CHD patients were positively correlated with SYNTAX scores from coronary angiography and increased with the severity of vascular stenosis.Conclusion:Elevated serum lncRNA-TUG1 levels in CHD patients suggest that lncRNA-TUG1 may serve as a novel and valuable diagnostic biomarker for CHD,with potential utility in differentiating CHD from other cardiac diseases.展开更多
目的探究食管鳞状细胞癌(ESCC)组织中长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)的表达水平及临床意义。方法收集2013年10月至2015年10月在渭南市中心医院行外科手术治疗的103例ESCC患者的肿瘤组织及癌旁组织标本。采用实时定量PCR(re...目的探究食管鳞状细胞癌(ESCC)组织中长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)的表达水平及临床意义。方法收集2013年10月至2015年10月在渭南市中心医院行外科手术治疗的103例ESCC患者的肿瘤组织及癌旁组织标本。采用实时定量PCR(real time qRT-PCR)法测定lncRNA-TUG1的表达水平。采用Cox比例风险回归模型分析ESCC患者预后的影响因素。结果lncRNA-TUG1在ESCC组织中的表达水平显著高于癌旁组织,差异有统计学意义(P<0.01)。lncRNA-TUG1的表达水平与患者的肿瘤分期、分化程度及淋巴结转移情况有关(P<0.05)。生存分析结果显示,lncRNA-TUG1高表达患者的5年生存率显著低于lncRNA-TUG1低表达患者(P<0.05)。淋巴结转移和lncRNA-TUG1高表达是ESCC患者预后生存的独立危险因素(P<0.05)。结论lncRNA-TUG1在ESCC组织中的表达水平较高,且与患者的预后显著相关。展开更多
[目的]检测长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)在胃癌组织中的表达情况,分析lncRNA-TUG1表达与胃癌患者临床病理参数及预后的关系。[方法]收集入住的85例胃癌患者的癌组织及其癌旁正常胃组织,采用实时定量PCR(real-time PCR)...[目的]检测长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)在胃癌组织中的表达情况,分析lncRNA-TUG1表达与胃癌患者临床病理参数及预后的关系。[方法]收集入住的85例胃癌患者的癌组织及其癌旁正常胃组织,采用实时定量PCR(real-time PCR)法检测组织样本中lncRNA-TUG1的表达水平。分析胃癌组织中lncRNA-TUG1表达与患者临床病理参数的关系,采用Kaplan-Meier生存模型分析lncRNA-TUG1表达对胃癌患者预后的影响。[结果]胃癌组织中lncRNA-TUG1表达水平显著高于癌旁正常胃组织(5.32±1.39 vs 1.24±0.31,t=-26.413,P<0.001),且lncRNA-TUG1表达与患者的肿瘤分化程度、浸润深度、淋巴结转移和TNM分期有关(P均<0.05)。Log-Rank检验结果显示,高表达lncRNATUG1胃癌患者的术后5年生存率和中位生存时间均显著低于低表达lncRNA-TUG1胃癌患者(P均<0.05)。[结论]胃癌组织中lncRNA-TUG1表达增加,且与患者较差的临床病理参数和不良预后相关。展开更多
目的探索酮还原酶家族1成员C3(aldo-keto reductase family 1 member C3,AKR1C3)对乳腺癌恶性细胞生物学行为的干预作用及对程序性细胞死亡蛋白/程序性死亡-配体1(programmed cell death protein1/programmed death-ligand1,PD-1/PD-L)...目的探索酮还原酶家族1成员C3(aldo-keto reductase family 1 member C3,AKR1C3)对乳腺癌恶性细胞生物学行为的干预作用及对程序性细胞死亡蛋白/程序性死亡-配体1(programmed cell death protein1/programmed death-ligand1,PD-1/PD-L)通路的影响。方法把MCF-7人乳腺癌细胞中NC组和AKR1C3组分别转染空质粒和AKR1C3质粒,采用MTT法检测转染后24 h、48 h、72 h细胞活力;采用流式细胞技术测定各组细胞的存活率以及早期、晚期凋亡比例;通过Transwell实验对各组细胞的迁移和侵袭能力进行检测;通过Western blot检测各组细胞PD-1、PD-L1、蛋白激酶B(protein kinase b,AKT)蛋白表达水平。使用C57BL/6小鼠构建荷瘤模型,将采用人乳腺癌MCF-7细胞转染NC质粒和AKR1C3质粒进行细胞荷瘤,每3 d测量瘤体积,持续21 d,绘制两组小鼠肿瘤生长曲线,并于实验终点测量肿瘤质量。结果相较于NC组,AKR1C3组细胞活力降低(P<0.05),并且具有时间依赖效应(P<0.05),迁移和侵袭能力降低(P<0.05),早期凋亡和晚期凋亡比例升高(P<0.05),PD-1、PD-L1、AKT蛋白表达水平降低(P<0.05)。动物实验表明,AKR1C3组小鼠肿瘤体积降低,肿瘤质量下降(P<0.05)。结论AKR1C3可以抑制人乳腺癌细胞恶性生物学行为,抑制PD-1/PDL1信号通路蛋白表达。展开更多
基金supported by the China Postdoctoral Science Foundation(Special Support,Grant No.2018T110318)the Innovation and Entrepreneurship Training Program for College Students(Grant No.S202110226047).
文摘Objectives:Accumulating evidence suggests that people living in cold regions have a higher risk of developing coronary atherosclerotic heart disease(CHD).Long non-coding RNAs(lncRNAs)have been implicated in the pathogenesis and treatment of a variety of diseases.The present study aimed to investigate the serum level of lncRNA-taurine upregulated gene 1(TUG1)in patients with CHD and assess its potential as a diagnostic biomarker.This study aimes to investigate the serum level of lncRNA-TUG1 in patients with CHD and assess its potential as a diagnostic biomarker.Methods:The Gene Expression Omnibus(GEO)database was employed to identify the potential lncRNAs serving as biomarkers for CHD.To validate lncRNA-TUG1,232 subjects were enrolled in both test and diagnostic cohorts.Serum lncRNA-TUG1 levels were measured by RT-qPCR.The association between lncRNA-TUG1 levels and CHD severity was analyzed using Pearson's correlation test.Diagnostic value was assessed by receiver operating characteristic(ROC)curve analysis and compared with established cardiac biomarkers.Results:LncRNA-TUG1 was identified in the GEO database as a potential biomarker for CHD.Serum lncRNA-TUG1 levels were significantly higher in CHD patients compared with healthy controls and non-CHD patients.CRP levels also differed between CHD and non-CHD groups,while other biomarkers showed no significant differences.ROC curve analysis demonstrated that lncRNA-TUG1 could distinguish CHD from non-CHD patients,with an area under the curve(AUC)of 0.8916,which was higher than that of conventional biomarkers such as cTnI.At a cut-off value of 2.311,the sensitivity and specificity of lncRNA-TUG1 were 61.63%and 97.67%,respectively,surpassing the diagnostic performance of cTnI.Furthermore,lncRNA-TUG1 levels in CHD patients were positively correlated with SYNTAX scores from coronary angiography and increased with the severity of vascular stenosis.Conclusion:Elevated serum lncRNA-TUG1 levels in CHD patients suggest that lncRNA-TUG1 may serve as a novel and valuable diagnostic biomarker for CHD,with potential utility in differentiating CHD from other cardiac diseases.
文摘目的探究食管鳞状细胞癌(ESCC)组织中长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)的表达水平及临床意义。方法收集2013年10月至2015年10月在渭南市中心医院行外科手术治疗的103例ESCC患者的肿瘤组织及癌旁组织标本。采用实时定量PCR(real time qRT-PCR)法测定lncRNA-TUG1的表达水平。采用Cox比例风险回归模型分析ESCC患者预后的影响因素。结果lncRNA-TUG1在ESCC组织中的表达水平显著高于癌旁组织,差异有统计学意义(P<0.01)。lncRNA-TUG1的表达水平与患者的肿瘤分期、分化程度及淋巴结转移情况有关(P<0.05)。生存分析结果显示,lncRNA-TUG1高表达患者的5年生存率显著低于lncRNA-TUG1低表达患者(P<0.05)。淋巴结转移和lncRNA-TUG1高表达是ESCC患者预后生存的独立危险因素(P<0.05)。结论lncRNA-TUG1在ESCC组织中的表达水平较高,且与患者的预后显著相关。
文摘[目的]检测长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)在胃癌组织中的表达情况,分析lncRNA-TUG1表达与胃癌患者临床病理参数及预后的关系。[方法]收集入住的85例胃癌患者的癌组织及其癌旁正常胃组织,采用实时定量PCR(real-time PCR)法检测组织样本中lncRNA-TUG1的表达水平。分析胃癌组织中lncRNA-TUG1表达与患者临床病理参数的关系,采用Kaplan-Meier生存模型分析lncRNA-TUG1表达对胃癌患者预后的影响。[结果]胃癌组织中lncRNA-TUG1表达水平显著高于癌旁正常胃组织(5.32±1.39 vs 1.24±0.31,t=-26.413,P<0.001),且lncRNA-TUG1表达与患者的肿瘤分化程度、浸润深度、淋巴结转移和TNM分期有关(P均<0.05)。Log-Rank检验结果显示,高表达lncRNATUG1胃癌患者的术后5年生存率和中位生存时间均显著低于低表达lncRNA-TUG1胃癌患者(P均<0.05)。[结论]胃癌组织中lncRNA-TUG1表达增加,且与患者较差的临床病理参数和不良预后相关。
